Scarica l'app Stockscreener
2.76
1.08%
-0.03
Dopo l'orario di chiusura:
2.74
-0.02
-0.72%
Precedente Chiudi:
$2.79
Aprire:
$2.76
Volume 24 ore:
37,832
Relative Volume:
0.21
Capitalizzazione di mercato:
$93.39M
Reddito:
-
Utile/perdita netta:
$-13.27M
Rapporto P/E:
-16.83
EPS:
-0.164
Flusso di cassa netto:
$-7.70M
1 W Prestazione:
-4.83%
1M Prestazione:
+20.00%
6M Prestazione:
+162.86%
1 anno Prestazione:
+78.06%
Intervallo 1D:
$2.74
$2.7983
Intervallo di 1 settimana:
$2.67
$3.06
Portata 52W:
$0.8075
$3.11
Okyo Pharma Limited Stock (OKYO) Company Profile
Nome
Okyo Pharma Limited
Settore
Industria
Telefono
-
Indirizzo
-
Confronta OKYO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
2.76 | 103.43M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Okyo Pharma Limited Borsa (OKYO) Ultime notizie
Will OKYO Pharma Limited stock benefit from AI tech trendsExplosive market performance - jammulinksnews.com
What institutions are buying OKYO Pharma Limited stock nowConsistently exceptional gains - jammulinksnews.com
OKYO Pharma reports promising phase 2 results for urcosimod in neuropathic corneal pain - Pharmafile
What drives OKYO Pharma Limited stock priceAccelerated wealth expansion - Autocar Professional
Is OKYO Pharma Limited a good long term investmentPhenomenal trading returns - Autocar Professional
OKYO Pharma Limited Stock Analysis and ForecastSuperior portfolio returns - jammulinksnews.com
What analysts say about OKYO Pharma Limited stockRapid-fire capital growth - jammulinksnews.com
OKYO Pharma Secures $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain - VisionMonday.com
OKYO Pharma CEO details positive results from Phase 2 urcosimod trialICYMI - Proactive financial news
OKYO Pharma Secures $1.9M Non-Dilutive Funding to Advance Urcosimod Development - AInvest
OKYO Pharma announces positive results from phase 2 trial of urcosimod for neuropathic corneal pain - Ophthalmology Times
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding - GlobeNewswire
OKYO Pharma receives $1.9 million non-dilutive funding for lead drug development - Investing.com Nigeria
Small cap wrap: Digi Power X, American Resources, OKYO Pharma, Lisata Therapeutics... - Proactive financial news
OKYO Slides Despite Fresh R&D Funding - Baystreet.ca
OKYO Pharma secures $1.9 million in non-dilutive funding for eye drug - Investing.com Canada
Okyo Pharma Obtains $1.9 Million Non-Dilutive Funding - MarketScreener
OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development - TipRanks
OKYO Pharma bolsters ocular pain program with $1.9M non-dilutive financing - Proactive financial news
OKYO Pharma secures $1.9 million in non-dilutive funding for eye drug By Investing.com - Investing.com South Africa
OKYO’s Market Whiplash: 86.16% YTD Rise, -1.66% Plunge in 30 Days - investchronicle.com
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain - MarketScreener
OKYO Secures $1.9M to Fast-Track Revolutionary Eye Pain Drug with No Current FDA Treatment - Stock Titan
OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data By Investing.com - Investing.com South Africa
OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data - Investing.com Australia
OKYO Pharma Limited Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain - MarketScreener
OKYO Pharma Receives Positive Buy Rating from H.C. Wainwright - AInvest
Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation - TipRanks
OKYO posts trial data for lead drug in eye pain (OKYO:NASDAQ) - Seeking Alpha
OKYO Pharma reports positive Phase 2 data in treating Neuropathic Corneal Pain - Proactive financial news
Small cap wrap: OKYO Pharma, North Bay Resources, Nevis Brands, Nextech3D.ai... - Proactive financial news
OKYO Pharma Says Phase 2 Study of Urcosimod Showed 'Marked Reduction' in Neuropathic Corneal Pain Scores - MarketScreener
OKYO Pharma stock surges after positive Phase 2 results for eye pain drug - Investing.com Australia
OKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal Pain - TipRanks
OKYO Pharma reports positive top-line results from Phase 2 urcosimod trial - Investing.com Nigeria
Okyo Pharma Limited Azioni (OKYO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):